MEM
MEMPHASYS LIMITED.
$0.0050
0.00%
Market cap
$15M
Turnover
$357
Last price
$0.0050
Day change
0.00%
Announcements
17
Range, past year
Open 0.005 · Low 0.003 · Now 0.005 · High 0.009
Open MEM in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.
MEM momentum and trend analysis
Our analysis
Independent analysis generated by Stock Trade Intelligence
as at 2026-09-28.
Momentum quality
29/100
Wyckoff phase
Downtrend2d
Trend stage
Breakdown
1 Day
+0.0%
1 Week
+0.0%
1 Month
+0.0%
1 Year
+0.0%
RSI
43
Avg daily range
15.9%
MEMPHASYS LIMITED. scores 29 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Breakdown.
On the Wyckoff cycle it sits in Downtrend, where it has been for 2 trading days. The weekly timeframe reads Downtrend, which agrees with the daily view.
Against the wider market it is currently underperforming and the institutional accumulation signal reads low.
Points to watch
- 60d drawdown -37.5%
- High volatility (ATR 15.9%)
- Thin liquidity
- Risk rating: Very High
- Composite downside risk elevated
Browse the whole market by signal:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highsMEM announcements
Recent price-sensitive releases.
- 2026-09-25 Potential Expedited FDA Pathway to US IVF Market Progress Report
- 2026-09-18 Memphasys Secures European Felix Agreement Progress Report
- 2026-09-03 Felix Registration Achieved in Turkey, Sales Commence Progress Report
- 2026-09-01 EUR526,500 Nordic Agreement Expands Felix European Footprint Progress Report
- 2026-08-31 Appendix 4E and 2026 Annual Report Annual Report | Top 20 shareholders | Preliminary Final Report | Full Year Accounts | Full Year Audit Review | Full Year Directors' Statement | Full Year Directors' Report
- 2026-08-28 Felix Early Thai FDA Approval, Commercial Launch Accelerates Progress Report
- 2026-08-20 Felix Registration Achieved in Vietnam and Cartridge Order Progress Report
More Health Care stocks
Most traded in the same sector.